Related Experiment Videos

A homogeneous cell-based assay to identify N-linked carbohydrate processing inhibitors

A Datti1, R S Donovan, B Korczak

  • 1GlycoDesign Inc., Toronto, Ontario, Canada. adatti@glycodesign.com

Insights

Researchers developed a cell-based assay to find anticancer drugs that block sugar molecule (beta1-6GlcNAc-branched glycan) production. This assay identifies compounds that protect tumor cells from a toxic lectin, aiding cancer research.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Oncology

Background:

  • Malignant transformation involves changes in cell surface glycosylation.
  • N-linked oligosaccharides with beta1-6GlcNAc branches correlate with tumor invasion and metastasis.

Purpose of the Study:

  • To develop a cell-based assay for identifying compounds that inhibit beta1-6GlcNAc-branched glycan biosynthesis.
  • To find potential anticancer agents that block specific glycan structures without causing significant cell death.

Main Methods:

  • A homogeneous cell-based assay using MDAY-D2 tumor cells was developed.
  • The assay detects compounds that block beta1-6GlcNAc-branched glycan expression by assessing protection against the cytotoxic plant lectin leukoagglutinin.
  • Alkaline phosphatase activity, which is proportional to cell number, was measured spectrophotometrically to quantify cell viability.

Main Results:

  • The assay successfully identified agents that inhibit beta1-6GlcNAc-branched glycan expression.
  • The alkaline phosphatase assay could detect as few as 1,500 cells.
  • The assay demonstrated adaptability for high-throughput screening with a coefficient of variation of 4.2% for controls.

Conclusions:

  • The developed cell-based assay is effective for screening compounds that inhibit beta1-6GlcNAc-branched glycan biosynthesis.
  • This assay format shows potential for broader applications in high-throughput screening for compounds targeting other cellular growth inhibitors.

Related Concept Videos